IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI

Amna Ameer; Farhan Akhtar; Hafeez Ud Din; Rabia Ahmad

doi:10.51253/pafmj.v71i1.4687

Authors

Amna Ameer Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Farhan Akhtar Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Hafeez Ud Din Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Rabia Ahmad Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v71i1.4687

Keywords:

Androgen receptor, Triple Negative Breast Carcinoma, Breast carcinoma, Hormone receptors, Prognosis

Abstract

Objective: To determine the frequency of immunohistochemical expression of androgen receptor in triple
negative breast carcinoma.

Study Design: Cross sectional study.

Duration and Place of Study: This study included 30 cases confirmed as triple negative breast carcinoma at
Armed Forces Institute of Pathology Rawalpindi, from Jan to Jul 2018.

Methodology: Anti-androgen receptor antibody was applied and assessed. Positive expression was defined as
greater and equal to 10% nuclear immunostaining. SPSS-24 was used for analyzing data.

Results: Out of 30 cases of triple negative breast carcinoma (TNBC), all patients were female. Patients’ ages
ranged between 21-72 years with a mean age of 46.35 years and a standard deviation of ± 13.4. Androgen receptor expression was positive in 8 cases (27%) of all triple negative breast carcinomas. Out of these androgen receptor (AR) triple negative breast carcinomas; all 8 cases were of histological subtype invasive ductal (mammary) carcinoma, non special type, 7 cases (23%) were of histological grade 3 and 1 was of histological grade 2.

Conclusion: Androgen receptor expression is observed in 8 cases (27%) of triple negative breast carcinoma cases. Such patients can be selected as candidates for anti- androgen receptor targeted therapy.